About
ThirtyFiveBio develops therapeutic solutions targeting gut epithelial dysfunction to treat ulcerative colitis by inhibiting GPR35 and protecting gut epithelial cells from inflammatory damage.
Explore thirtyfivebio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.